Global contract development and manufacturing organisation (CDMO) Recipharm, today announces that it is expanding its pMDI product development expertise to accommodate the increasing demand from pharmaceutical companies as they begin the transition to the next generation of propellants over the coming years. These new propellant gases have 90% to 99.9% lower global warming potential (GWP) than HFA134a.
Jean-François Hilaire, Head of the Advanced Delivery Systems business unit at Recipharm, said: “We are committed to decarbonisation and helping our customers meet their sustainability objectives by transitioning their pMDI products to the new propellants and helping reduce the Green House Gas (GHG) emissions from their products. Recipharm is working hard to help customers identify and reduce GHG emissions related to both product manufacturing and usage with the common aim of meeting the requirements of the Paris Agreement of limiting global warming to 1.5 degrees Celsius.”
“Not only that, but as other industries are also asked by regulators to phase-out propellants with higher GWP, it’s likely that the existing propellants will become less available and more costly. It is therefore important that we prepare to work with new propellants to safeguard the supply of pMDIs to patients. 2022 is an exciting year for Recipharm and our investment in these new manufacturing lines will support us in introducing more sustainable propellants to our pMDI production.”
Furthermore, Recipharm’s in-house product development expertise will be complemented by a collaboration with Professor Darragh Murnane and his research group at the University of Hertfordshire to develop tools, techniques and transition pathways. Recipharm’s device development team recently completed a three-year Innovate UK (IUK) Knowledge Transfer Partnership research programme with the University of Hertfordshire and the University of East London. The programme developed device modelling toolkits to accelerate and tailor device design to pMDI aerosol product performance needs.
Professor Murnane, Professor of Pharmaceutics & Associate Dean (Business and Enterprise) at the University of Hertfordshire, said: “We are excited about the next phase of working with Recipharm. We’re really looking forward to addressing the challenges of the reformulation for low-GWP inhalation products with the Recipharm team.”
The expansion of pMDI product development services announced today complements Recipharm’s existing capability to offer customers pMDI valves suitable for both new propellants. As a result, Recipharm can offer an integrated service including valve selection and product reformulation enabling pharmaceutical companies to transition their pMDI products to next-generation propellants.
Contact information:
Marcus Smith, Head of Communications at Recipharm, marcus.smith@recipharm.com
For media enquiries, please contact Aranda Rahbarkouhi, aranda@ramarketingpr.com,+44 191 222 1242
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
